IMG 008
Alternative Names: IMG-008Latest Information Update: 13 Apr 2023
Price :
$50 *
At a glance
- Originator Inmagene
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Interleukin 36 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Generalised pustular psoriasis; Hidradenitis suppurativa
Most Recent Events
- 13 Apr 2023 Preclinical trials in Hidradenitis suppurativa and Generalized pustular psoriasis in USA (Parenteral) (Inmagene pipeline, April 2023)
- 09 Feb 2023 Inmagene plans a phase I trial in Healthy volunteers
- 06 Feb 2023 Inmagene plans a phase I trial in Generalized pustular psoriasis and Hidradenitis suppurativa (In volunteers) in the first half of 2024 (Parenteral) (Inmagene pipeline, September 2023)